U.S. Markets open in 5 hrs 26 mins

Kelyniam Global, Inc. (KLYG)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.11720.0000 (0.00%)
At close: 09:30AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1172
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1172 - 0.1172
52 Week Range0.0800 - 0.9000
Avg. Volume51,693
Market Cap2.402M
Beta (5Y Monthly)-1.72
PE Ratio (TTM)9.77
EPS (TTM)0.0120
Earnings DateMay 18, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Kelyniam Global, Inc., Announces Strategic Licensing Agreement with Fin-ceramica faenza spa to Market Hydroxyapatite Cranial Implant in the U.S.

    Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial PEEK implants today announced that it has entered into a strategic licensing agreement with Fin-ceramica faenza spa to market the company's hydroxyapatite patient specific implant. This bio-mimetic ceramic biomaterial is based on macro and micro porous Hydroxyapatite (HA), a major (70%) component of human bone. The specific bio-mimetic chemical composition combined with an elevated interconnected porosity play a role in

  • PR Newswire

    Kelyniam Global Receives U.S. Patent for Integrated Fixation Tabs

    Kelyniam Global, a leader in the design and manufacture of custom cranial implants, is pleased to announce that the United States Patent and Trademark Office has issued the company an Issue Notification for a patent covering the company's Integrated Fixation Tabs, currently marketed as IFS Tabs or KwikTabs. The US patent covers the integration of fixation appendages into a cranial implant and their design. The patent was filed in 2014 and will run through 2037.

  • PR Newswire

    Kelyniam Global Releases 3rd Quarter 2021 Financials

    Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its third quarter ended September 30, 2021.